Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Abril 2024 - 2:00PM
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology
company leveraging its core competencies in immune cell modulation
and protein engineering to develop novel, investigational
engineered cytokine therapies designed to address areas of unmet
need for patients with a variety of cancers, today announced that
on April 1, the Company granted to four newly hired employees (i)
non-statutory stock options to purchase an aggregate of 25,675
ordinary shares of the Company and (ii) restricted stock units with
respect to an aggregate of 13,825 ordinary shares of the Company,
pursuant to the Company’s 2024 Inducement Stock Option and
Incentive Plan, each as an inducement material to the new employees
entering into employment with the Company in accordance with Nasdaq
Listing Rule 5635(c)(4).
The stock options have an exercise price of $4.85 per share,
which is equal to the closing price per share of the Company’s
ordinary shares as reported by Nasdaq on April 1, 2024. The options
have a ten-year term and vest over four years, with 25% of the
original number of shares vesting on the first anniversary of the
grant date and 6.25% of the shares underlying the options vesting
quarterly thereafter, subject to such employee’s continued service
with the Company through the applicable vesting dates. Each of the
stock options is subject to the terms and conditions of a stock
option award agreement covering the grant and the Company’s 2024
Inducement Stock Option and Incentive Plan. The restricted stock
units vest over four years, 25% per year on the anniversary of the
grant date, subject to such employee’s continued service with the
Company through the applicable vesting dates. Each of the
restricted stock units is subject to the terms and conditions of a
restricted stock award agreement covering the grant and the
Company’s 2024 Inducement Stock Option and Incentive Plan.
About Mural OncologyMural Oncology is
leveraging its novel protein engineering platform to develop
cytokine-based immunotherapies for the treatment of cancer. By
combining our expertise in cytokine biology and immune cell
modulation and our protein engineering platform, we are developing
medicines to deliver meaningful and clinical benefits to people
living with cancer. Our mission is to broaden the potential
and reach of cytokine-based immunotherapies to improve the lives of
patients. Our lead candidate, nemvaleukin, is currently in
potentially registrational trials in mucosal melanoma and
platinum-resistant ovarian cancer. Mural Oncology has its
registered office in Dublin, Ireland, and its primary facilities in
Waltham, Mass. For more information, visit Mural Oncology’s website
at www.muraloncology.com and follow us on LinkedIn and X.
Contacts
Investors:David Borah,
CFAdavid.borah@muraloncology.com
Media:Katie
Sullivankatie.sullivan@muraloncology.com
Mural Oncology (NASDAQ:MURA)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Mural Oncology (NASDAQ:MURA)
Gráfica de Acción Histórica
De May 2023 a May 2024